Sample Buyer Readiness Record

• This record describes what Northwind Encounter Summarizer (version 2.1) supplied for a buyer pilot discussion. It is based on materials supplied by the company and makes no determination about safety, effectiveness, clinical utility, return on investment or deployment readiness.
• 3 claim(s) were assessed by documentation rules: 1 partially documented, 1 conflicting, 1 not supplied.
• 7 item(s) require local health-system determination. 1 documentation domain(s) lack supplied answers and 0 are blocked. Supplied answers are not independently verified.
• No composite score, rating, endorsement or proceed/pause decision is produced by this record.

Product

Northwind Encounter Summarizer

Assessed version

2.1

Intended use

Drafts an encounter summary note from ambient conversation and prior record context for clinician review before signing.

Target user

Attending physicians and advanced practice providers

Target population

Adult ambulatory primary care patients

Setting

Outpatient primary care clinics

Requested buyer action

pilot discussion

Company-supplied statements, not independently verified. These notes do not change computed evidence states or establish equivalence, successful reproduction or benefit.

Tested configuration and deployment differences

Not supplied

Not supplied

Availability, inspection and reproduction

Not supplied

Not supplied

Outcome measurement and missing results

Not supplied

Not supplied

Correction review and original-source retention

Not supplied

Not supplied

Source shows where each domain's information came from. Company-supplied answers are recorded as supplied and are not independently verified.

• "Reduces documentation time per encounter" — Partially documented. As stated, this claim may exceed what is supported by the supplied materials and may warrant clarification.
• "Draft notes are rated acceptable by reviewing clinicians in most encounters" — Conflicting. As stated, this claim may exceed what is supported by the supplied materials and may warrant clarification.
• "Improves clinician satisfaction" — Not supplied. As stated, this claim may exceed what is supported by the supplied materials and may warrant clarification.

• Local data availability, mapping and completeness in the buying health system requires local health-system determination.
• Local workflow fit, staffing and oversight capacity requires local health-system determination.
• Local performance in the buyer's own population and setting is not established from supplied materials.
• Local roles — intended user, champion, buyer/budget owner and final institutional authorizer — require local health-system determination.
• Who supplies reviewer time, information and authority, and who supplies support, training and fallback, requires local health-system determination.
• Source "Internal time-on-task analysis, 2024" setting (Academic outpatient clinic) differs from the stated target setting (Outpatient primary care clinics); local applicability requires local health-system determination.
• Company-stated local evaluation assumptions to confirm locally: Assumes local note templates can be mapped and that clinicians accept a draft-first workflow.

• Read access to problem list, medications and prior notes
• Ambient audio capture hardware in the exam room
• SSO and role mapping from the health system directory

• How is human review and override implemented, and is it enforced or optional in the workflow?
• Who is accountable when output is incorrect, incomplete or not acted on?
• What is documented about how output is presented to the target user?
• For generated documentation: how is authorship and source attribution shown in the record, and how are corrections handled?

• How are model or product version changes communicated to the health system?
• What evidence is regenerated when a version changes, and what is carried forward?
• What monitoring is in place after go-live, and what is reported back to the customer?
• What triggers a re-review of prior evidence under the company's own change-control process?

1. For "Reduces documentation time per encounter", the exact endpoint, design and population may warrant clarification.
2. Supplied sources for "Draft notes are rated acceptable by reviewing clinicians in most encounters" are marked conflicting; which source is current and why may warrant clarification.
3. What source supports the claim "Improves clinician satisfaction"? This is not supplied.
4. Monitoring and change control: not established from supplied materials; documentation may warrant clarification.
5. For "Reduces documentation time per encounter": which endpoint type does each supplied source actually measure — technical accuracy, acceptance/use, clinician or workflow behavior, clinical outcome, equity, economic? One endpoint type is not evidence for another; this may warrant clarification.
6. For "Draft notes are rated acceptable by reviewing clinicians in most encounters": which endpoint type does each supplied source actually measure — technical accuracy, acceptance/use, clinician or workflow behavior, clinical outcome, equity, economic? One endpoint type is not evidence for another; this may warrant clarification.
7. For "Improves clinician satisfaction": which endpoint type does each supplied source actually measure — technical accuracy, acceptance/use, clinician or workflow behavior, clinical outcome, equity, economic? One endpoint type is not evidence for another; this may warrant clarification.
8. Roles: who is the intended user, who is the clinical or operational champion, who is the buyer/budget owner, and who is the final institutional authorizer? These roles may be held by different people and require local health-system determination.
9. Reviewer resources: who supplies reviewer time, who supplies the information reviewers need, and who holds the authority to act on review findings? Naming an overseer is not evidence of review capacity.
10. Support: who supplies user support, training and a documented fallback when the product is unavailable or its output is not used?
11. Excluded or absent populations: which patient groups, settings or sites were excluded from, or absent in, the supplied sources? This is separate from any missing source fields.
12. Unknown denominators: for each supplied source, is the denominator (eligible encounters, users or patients) known? Unknown coverage cannot establish representativeness of the buyer's population.
13. Model training: is any customer data (including prompts, outputs or corrections) used to train or tune models, and can the customer opt out?
14. Retention and deletion: how long is customer data retained, and how is deletion requested, performed and confirmed?
15. Subprocessors: which subprocessors (including model or hosting providers) handle customer data, and how are changes notified?
16. Processing region: in which regions is customer data processed and stored?
17. Disablement: how can the health system disable the product or specific functions, how quickly, and what happens to in-flight work?
18. Permission boundaries: which systems, data and actions can the product access, and how are those permissions scoped, reviewed and revoked?
19. AI-event logging: which AI inputs, outputs, actions and overrides are logged, who can access the logs, and for how long are they kept?
20. Tested configuration: for each source, record the evaluated product/model version, evaluation date, API or consumer interface, system instructions, safeguards, available tools and workflow. Compare them with the intended deployment and name untested differences. An identical model name does not establish equivalent behavior.
21. Required human approval: which outputs or actions require human approval before they take effect, and is that enforced by the product or by policy?
22. Post-update monitoring: after a model or configuration update, what is monitored, by whom, and what triggers rollback or notification to the health system?
23. Evidence reproducibility: distinguish source materials available, actually inspected and independently reproduced. For each source, identify restrictions, operator/date, input/code/dependency versions, expected versus actual outputs and failed or blocked attempts. A repository link is not a successful independent rerun.
24. Outcome ascertainment: identify the endpoint, comparator, observation period, eligible/assigned/assessed denominators by group, missing outcomes and reasons, effect estimate and uncertainty, and sensitivity analyses. Preserve null, adverse, inconclusive and unmeasured findings rather than reporting only successful outcomes.
25. Correction review: retain the original source, first generated output and each revision; compare both resolved and newly introduced errors. Identify the human reviewer, unresolved disagreements and final version approval. A correction pass does not establish an error-free record.
26. How would performance be evaluated locally before and after go-live, and by whom?

• Product version changed (1.8 → 2.1): Evidence tied to version 1.8 is flagged for review and is not automatically carried forward.

Limitations

• Based only on materials supplied by the company; nothing was independently verified.
• Generated or user-supplied content in this record is not independently verified evidence.
• No patient-level data, protected health information or clinical content was reviewed.
• This record is not certification, validation, regulatory review, compliance review, safety review or endorsement.
• This tool does not establish validation, compliance, deployment readiness, clinical utility, return on investment or buyer demand.
• Local applicability cannot be established from supplied materials and requires local health-system determination.
• Speed or time savings is not evidence of clinical benefit.
• Acceptability or satisfaction is not evidence of technical accuracy.
• Unknown coverage or denominators cannot imply representativeness.
• Naming an overseer is not proof of oversight capacity.
• Results apply to the tested configuration. A shared model name does not establish equivalent behavior across API, consumer interface, instructions, tools, safeguards or workflows.
• Evidence availability, inspection and independent reproduction are separate questions. Company-supplied accounts of any of them remain unverified in this record.
• A null result is no demonstrated benefit on the measured endpoint under the studied conditions, not proof that benefit is absent. Incomplete outcome measurement can limit interpretation; uncertainty and missingness must be retained.
• An automated correction may remove one error while introducing another. This record does not authorize clinical use or replace required human review, local evaluation or a pilot.
• Evidence states in this record are computed from the supplied materials. Where the submitting company recorded its own interpretation of a claim, that interpretation is shown as submitter interpretation only and does not change the computed state.

Unresolved items

• Reduces documentation time per encounter — Partially documented
• Draft notes are rated acceptable by reviewing clinicians in most encounters — Conflicting
• Improves clinician satisfaction — Not supplied
• Monitoring and change control — Not supplied
• Privacy / security materials — Partially documented
• Documentation / record pathway — Partially documented
• Open diligence question (not answered from supplied materials): Roles: who is the intended user, who is the clinical or operational champion, who is the buyer/budget owner, and who is the final institutional authorizer? These roles may be held by different people and require local health-system determination.
• Open diligence question (not answered from supplied materials): Reviewer resources: who supplies reviewer time, who supplies the information reviewers need, and who holds the authority to act on review findings? Naming an overseer is not evidence of review capacity.
• Open diligence question (not answered from supplied materials): Support: who supplies user support, training and a documented fallback when the product is unavailable or its output is not used?
• Open diligence question (not answered from supplied materials): Excluded or absent populations: which patient groups, settings or sites were excluded from, or absent in, the supplied sources? This is separate from any missing source fields.
• Open diligence question (not answered from supplied materials): Unknown denominators: for each supplied source, is the denominator (eligible encounters, users or patients) known? Unknown coverage cannot establish representativeness of the buyer's population.
• Open diligence question (not answered from supplied materials): Model training: is any customer data (including prompts, outputs or corrections) used to train or tune models, and can the customer opt out?
• Open diligence question (not answered from supplied materials): Retention and deletion: how long is customer data retained, and how is deletion requested, performed and confirmed?
• Open diligence question (not answered from supplied materials): Subprocessors: which subprocessors (including model or hosting providers) handle customer data, and how are changes notified?
• Open diligence question (not answered from supplied materials): Processing region: in which regions is customer data processed and stored?
• Open diligence question (not answered from supplied materials): Disablement: how can the health system disable the product or specific functions, how quickly, and what happens to in-flight work?
• Open diligence question (not answered from supplied materials): Permission boundaries: which systems, data and actions can the product access, and how are those permissions scoped, reviewed and revoked?
• Open diligence question (not answered from supplied materials): AI-event logging: which AI inputs, outputs, actions and overrides are logged, who can access the logs, and for how long are they kept?
• Open diligence question (not answered from supplied materials): Required human approval: which outputs or actions require human approval before they take effect, and is that enforced by the product or by policy?
• Open diligence question (not answered from supplied materials): Post-update monitoring: after a model or configuration update, what is monitored, by whom, and what triggers rollback or notification to the health system?
• Review required (company notes, if present, are unverified): Tested configuration: for each source, record the evaluated product/model version, evaluation date, API or consumer interface, system instructions, safeguards, available tools and workflow. Compare them with the intended deployment and name untested differences. An identical model name does not establish equivalent behavior.
• Review required (company notes, if present, are unverified): Evidence reproducibility: distinguish source materials available, actually inspected and independently reproduced. For each source, identify restrictions, operator/date, input/code/dependency versions, expected versus actual outputs and failed or blocked attempts. A repository link is not a successful independent rerun.
• Review required (company notes, if present, are unverified): Outcome ascertainment: identify the endpoint, comparator, observation period, eligible/assigned/assessed denominators by group, missing outcomes and reasons, effect estimate and uncertainty, and sensitivity analyses. Preserve null, adverse, inconclusive and unmeasured findings rather than reporting only successful outcomes.
• Review required (company notes, if present, are unverified): Correction review: retain the original source, first generated output and each revision; compare both resolved and newly introduced errors. Identify the human reviewer, unresolved disagreements and final version approval. A correction pass does not establish an error-free record.